Market closed
Lexicon Pharmaceuticals/$LXRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Ticker
$LXRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
285
Website
LXRX Metrics
BasicAdvanced
$262M
Market cap
-
P/E ratio
-$0.74
EPS
1.24
Beta
-
Dividend rate
Price and volume
Market cap
$262M
Beta
1.24
52-week high
$3.73
52-week low
$0.62
Average daily volume
4.5M
Financial strength
Current ratio
7.452
Quick ratio
7.248
Long term debt to equity
58.58
Total debt to equity
59.309
Interest coverage (TTM)
-12.32%
Management effectiveness
Return on assets (TTM)
-44.16%
Return on equity (TTM)
-136.09%
Valuation
Price to revenue (TTM)
40.254
Price to book
1.47
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-1.01
Growth
Revenue change (TTM)
886.60%
Earnings per share change (TTM)
-2.41%
3-year revenue growth (CAGR)
121.22%
3-year earnings per share growth (CAGR)
15.21%
What the Analysts think about LXRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
LXRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LXRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LXRX News
AllArticlesVideos
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
Reuters·17 hours ago
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
GlobeNewsWire·17 hours ago
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $262M as of December 21, 2024.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of December 21, 2024.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.